The median survival was 21.2 ± 2.6 months in MAP4K5-low group compared to 40.6 ± 6.2 months in patients whose tumor was MAP4K5-high (P = 0.02, log-rank test, Fig 6). This evidence concerns the gene MAP4K5 and neoplasm.